Fatty acid synthase

Classes

There are two principal classes of fatty acid synthases.

• Type I systems utilise a single large, multifunctional polypeptide and are common to both animals and fungi (although the structural arrangement of fungal and animal syntheses differ). A Type I fatty acid synthase system is also found in the CMN group of bacteria (corynebacteria, mycobacteria, and nocardia). In these bacteria, the FAS I system produces palmitic acid, and cooperates with the FAS II system to produce a greater diversity of lipid products.
• Type II is found in archaea, bacteria and plant plastids, and the mitochondria of animals, including humans, and is characterized by the use of discrete, monofunctional enzymes for fatty acid synthesis. Inhibitors of this pathway (FASII) are being investigated as possible antibiotics.

The mechanism of FAS I and FAS II elongation and reduction is the same, as the domains of the FAS II enzymes are largely homologous to their domain counterparts in FAS I multienzyme polypeptides. However, the differences in the organization of the enzymes - integrated in FAS I, discrete in FAS II - gives rise to many important biochemical differences.

The evolutionary history of fatty acid synthases are very much intertwined with that of polyketide synthases (PKS). Polyketide synthases use a similar mechanism and homologous domains to produce secondary metabolite lipids. Furthermore, polyketide synthases also exhibit a Type I and Type II organization. FAS I in animals is thought to have arisen through modification of PKS I in fungi, whereas FAS I in fungi and the CMN group of bacteria seem to have arisen separately through the fusion of FAS II genes.

Structure

Mammalian FAS consists of a homodimer of two identical protein subunits, in which three catalytic domains in the N-terminal section (-ketoacyl synthase (KS), malonyl/acetyltransferase (MAT), and dehydrase (DH)), are separated by a core region (known as the interdomain) of 600 residues from four C-terminal domains (enoyl reductase (ER), -ketoacyl reductase (KR), acyl carrier protein (ACP) and thioesterase (TE)). The interdomain region allows the two monomeric domains to form a dimer.

The conventional model for organization of FAS (see the 'head-to-tail' model on the right) is largely based on the observations that the bifunctional reagent 1,3-dibromopropanone (DBP) is able to crosslink the active site cysteine thiol of the KS domain in one FAS monomer with the phosphopantetheine prosthetic group of the ACP domain in the other monomer. Complementation analysis of FAS dimers carrying different mutations on each monomer has established that the KS and MAT domains can cooperate with the ACP of either monomer. and a reinvestigation of the DBP crosslinking experiments revealed that the KS active site Cys161 thiol could be crosslinked to the ACP 4'-phosphopantetheine thiol of either monomer. In addition, it has been recently reported that a heterodimeric FAS containing only one competent monomer is capable of palmitate synthesis.

The above observations seemed incompatible with the classical 'head-to-tail' model for FAS organization, and an alternative model has been proposed, predicting that the KS and MAT domains of both monomers lie closer to the center of the FAS dimer, where they can access the ACP of either subunit (see figure on the top right).

A low resolution X-ray crystallography structure of both pig (homodimer) and yeast FAS (heterododecamer) along with a ~6 Å resolution electron cryo-microscopy (cryo-EM) yeast FAS structure have been solved.

Substrate shuttling mechanism

The solved structures of yeast FAS and mammalian FAS show two distinct organizations of highly conserved catalytic domains/enzymes in this multi-enzyme cellular machine. Yeast FAS has a highly efficient rigid barrel-like structure with 6 reaction chambers which synthesize fatty acids independently, while the mammalian FAS has an open flexible structure with only two reaction chambers. However, in both cases the conserved ACP acts as the mobile domain responsible for shuttling the intermediate fatty acid substrates to various catalytic sites. A first direct structural insight into this substrate shuttling mechanism was obtained by cryo-EM analysis, where ACP is observed bound to the various catalytic domains in the barrel-shaped yeast fatty acid synthase. The cryo-EM results suggest that the binding of ACP to various sites is asymmetric and stochastic, as also indicated by computer-simulation studies

Regulation

Metabolism and homeostasis of fatty acid synthase is transcriptionally regulated by Upstream Stimulatory Factors (USF1 and USF2) and sterol regulatory element binding protein-1c (SREBP-1c) in response to feeding/insulin in living animals.

Although liver X receptors (LXRs) modulate the expression of sterol regulatory element binding protein-1c (SREBP-1c) in feeding, regulation of FAS by SREBP-1c is USF-dependent.

Acylphloroglucinols isolated from the fern Dryopteris crassirhizoma show a fatty acid synthase inhibitory activity.

Clinical significance

The FASN gene has been investigated as a possible oncogene. FAS is upregulated in breast and gastric cancers, as well as being an indicator of poor prognosis, and so may be worthwhile as a chemotherapeutic target. FAS inhibitors are therefore an active area of drug discovery research.

FAS may also be involved in the production of an endogenous ligand for the nuclear receptor PPARalpha, the target of the fibrate drugs for hyperlipidemia, and is being investigated as a possible drug target for treating the metabolic syndrome. Orlistat which is a gastrointestinal lipase inhibitor also inhibits FAS and has a potential as a medicine for cancer.

In some cancer cell lines, this protein has been found to be fused with estrogen receptor alpha (ER-alpha), in which the N-terminus of FAS is fused in-frame with the C-terminus of ER-alpha.

An association with uterine leiomyomata has been reported.

References

References

1. (2021-08-11). "Animal Fatty Acid Synthase: A Chemical Nanofactory". Chemical Reviews.
2. (February 1995). "Isolation and chromosomal mapping of genomic clones encoding the human fatty acid synthase gene". Genomics.
3. (Oct 1995). "Human fatty acid synthase: properties and molecular cloning". Proceedings of the National Academy of Sciences of the United States of America.
4. (Feb 2009). "The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative". Chemico-Biological Interactions.
5. "Entrez Gene: FASN fatty acid synthase".
6. (October 1975). "Regulation of synthesis of hepatic fatty acid synthetase: binding of fatty acid synthetase antibodies to polysomes". Proceedings of the National Academy of Sciences of the United States of America.
7. (May 1975). "Presence of two polypeptide chains comprising fatty acid synthetase". Proceedings of the National Academy of Sciences of the United States of America.
8. (April 1976). "Specific release of the thioesterase component of the fatty acid synthetase multienzyme complex by limited trypsinization". Proceedings of the National Academy of Sciences of the United States of America.
9. (July 2003). "Structural and functional organization of the animal fatty acid synthase". Progress in Lipid Research.
10. (October 2005). "Evolutionary implications of bacterial polyketide synthases". Molecular Biology and Evolution.
11. Fulmer T. (March 2009). "Not so FAS". Science-Business EXchange.
12. (1999). "Fundamentals of enzymology: the cell and molecular biology of catalytic proteins". Oxford University Press.
13. (March 2001). "Human fatty acid synthase: role of interdomain in the formation of catalytically active synthase dimer". Proceedings of the National Academy of Sciences of the United States of America.
14. Smith S. (December 1994). "The animal fatty acid synthase: one gene, one polypeptide, seven enzymes". FASEB Journal.
15. (May 1981). "Animal fatty acid synthetase. A novel arrangement of the beta-ketoacyl synthetase sites comprising domains of the two subunits". Journal of Biological Chemistry.
16. (March 1982). "Animal fatty acid synthetase. Identification of the residues comprising the novel arrangement of the beta-ketoacyl synthetase site and their role in its cold inactivation". Journal of Biological Chemistry.
17. (February 1998). "Differential affinity labeling of the two subunits of the homodimeric animal fatty acid synthase allows isolation of heterodimers consisting of subunits that have been independently modified". Journal of Biological Chemistry.
18. (September 2001). "Mapping the functional topology of the animal fatty acid synthase by mutant complementation in vitro". Biochemistry.
19. (April 1999). "Dibromopropanone cross-linking of the phosphopantetheine and active-site cysteine thiols of the animal fatty acid synthase can occur both inter- and intrasubunit. Reevaluation of the side-by-side, antiparallel subunit model". Journal of Biological Chemistry.
20. (February 2003). "Engineering of an active animal fatty acid synthase dimer with only one competent subunit". Chemistry and Biology.
21. (March 2005). "Structure and molecular organization of mammalian fatty acid synthase". Nature Structural and Molecular Biology.
22. (September 2008). "The crystal structure of a mammalian fatty acid synthase". Science.
23. (April 2007). "The crystal structure of yeast fatty acid synthase, a cellular machine with eight active sites working together". Cell.
24. (May 2010). "Direct structural insight into the substrate-shuttling mechanism of yeast fatty acid synthase by electron cryomicroscopy". Proceedings of the National Academy of Sciences of the United States of America.
25. (September 2010). "Mechanism of substrate shuttling by the acyl-carrier protein within the fatty acid mega-synthase". Journal of the American Chemical Society.
26. (January 1989). "Hormonal regulation of mouse fatty acid synthase gene transcription in liver". Journal of Biological Chemistry.
27. (August 2003). "Occupancy and function of the -150 sterol regulatory element and -65 E-box in nutritional regulation of the fatty acid synthase gene in living animals". Molecular and Cellular Biology.
28. (February 2007). "Direct interaction between USF and SREBP-1c mediates synergistic activation of the fatty-acid synthase promoter". Journal of Biological Chemistry.
29. (May 2001). "Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter". Molecular and Cellular Biology.
30. (November 2000). "Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta". Genes & Development.
31. (September 2006). "Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma". Bioorganic & Medicinal Chemistry Letters.
32. (January 2004). "Fatty acid synthase: a metabolic oncogene in prostate cancer?". Journal of Cellular Biochemistry.
33. (2007). "MRNA stability and overexpression of fatty acid synthase in human breast cancer cell lines". Anticancer Research.
34. (June 1997). "Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival". Human Pathology.
35. (May 2019). "Clinical importance of FASN in relation to HIF-1α and SREBP-1c in gastric adenocarcinoma". Life Sciences.
36. (April 7, 2017). "First Human Study Taking Place With Fatty Acid Synthase Inhibitor". oncotherapynetwork.com.
37. (May 2018). "Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy". Bioorganic & Medicinal Chemistry Letters.
38. (September 2014). "A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site". Nature Chemical Biology.
39. (February 2017). "Understanding the Intersections between Metabolism and Cancer Biology". Cell.
40. Sgro, Christopher David. (2009-01-01). "An investigation into the interdomain region of Caenorhabditis elegans fatty acid synthase and its implications as a drug target". La Trobe.
41. (August 2009). "Identification of a physiologically relevant endogenous ligand for PPARalpha in liver.". Cell.
42. (March 2011). "Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes.". Proceedings of the National Academy of Sciences of the United States of America.
43. (April 2010). "Fatty acid synthase as a potential therapeutic target in cancer". Future Oncology.
44. (September 2008). "Synthesis of novel beta-lactone inhibitors of fatty acid synthase". Journal of Medicinal Chemistry.
45. (2012). "Genome-wide linkage and association analyses implicate FASN in predisposition to uterine leiomyomata". American Journal of Human Genetics.